This approach has shown anti-leukemic efficacy comparable to combination therapy with CAR-T cells and anti-PD-1 antibodies (121), and has demonstrated improved eradication of CD19+PD-L1+ leukemia cells (122). Here, CD19 is linked to leukemia.